How can a company consistently bleeding billions trade at over $10 a share?

The answer might lie in Ramaswamy's implementation of Roivant's diversity, equity, and inclusion (DEI) initiative, called Roivant Social Ventures, during his CEO tenure. Launched in 2020 while Ramaswamy was still CEO, this initiative aimed to foster "DEI opportunities for future leaders in biopharma and biotech."

While  Ramaswamy vocally opposes ESG principles, Roivant's major institutional  investors—including Morgan Stanley, Viking Global, and BlackRock, the  very firms he criticizes by name—are among its largest stakeholders,  owning over 500 million shares. Ramaswamy himself holds more than 80 million shares, making him an essential partner of these major ESG funds.

In  a deeply ironic twist, Ramaswamy's anti-"woke" campaign is being  bankrolled by the profits reaped from the very policies he denounces.

More of why he's a fraud.